Oryzon Genomics S.A.

MCE ORY.MC

Oryzon Genomics S.A. Total Non-Current Liabilities for the year ending December 31, 2023: USD 9.61 M

Oryzon Genomics S.A. Total Non-Current Liabilities is USD 9.61 M for the year ending December 31, 2023, a -27.51% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Oryzon Genomics S.A. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 13.26 M, a -24.59% change year over year.
  • Oryzon Genomics S.A. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 17.59 M, a 37.35% change year over year.
  • Oryzon Genomics S.A. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 12.81 M.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
SV Wall Street
MCE: ORY.MC

Oryzon Genomics S.A.

CEO Dr. Carlos Manuel Buesa Arjol
IPO Date Dec. 14, 2015
Location Spain
Headquarters Sant Ferran 74
Employees 46
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

StockViz Staff

February 7, 2025

Any question? Send us an email